LIGAND PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 8, 2024

LGND$314.16+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except par value)

	March 31, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$50,093	$22,954
Short-term investments	260,500	147,355
Accounts receivable, net	28,435	32,917
Inventory	21,337	23,969
Income taxes receivable	—	6,395
Prepaid expenses	1,237	1,182
Other current assets	7,311	2,657
Total current assets	368,913	237,429
Deferred income taxes, net	—	214
Intangible assets, net	291,420	299,606
Goodwill	105,250	103,370
Long-term portion of financial royalty assets, net	65,710	62,291
Property and equipment, net	15,135	15,607
Operating lease right-of-use assets	6,028	6,062
Finance lease right-of-use assets	3,219	3,393
Equity method investment in Primrose Bio	10,469	12,595
Other investments	36,500	36,726
Other assets	11,225	9,923
Total assets	$913,869	$787,216
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$1,893	$2,427
Accrued liabilities	12,430	12,467
Income taxes payable	1,138	—
Deferred revenue	1,227	1,222
Current contingent liabilities	127	256
Current operating lease liabilities	1,000	403
Current finance lease liabilities	3	7
Total current liabilities	17,818	16,782
Long-term deferred revenue	3,065	1,444
Long-term contingent liabilities	2,888	2,942
Deferred income taxes, net	50,606	31,622
Long-term operating lease liabilities	5,191	5,755
Other long-term liabilities	27,780	27,758
Total liabilities	107,348	86,303
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 17,924 and 17,556 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	18	18
Additional paid-in capital	218,258	198,696
Accumulated other comprehensive loss	(910)	(817)
Retained earnings	589,155	503,016
Total stockholders' equity	806,521	700,913
Total liabilities and stockholders' equity	$913,869	$787,216

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.